Robert Lebuhn is Director at ENZON PHARMACEUTICALS INC (ENZN). They have made 6 open-market trades across 1 company since 2010, most recently 2013-09-19.
CIK 0001007931
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ENZN | 42,189 | $1.9M |
Shares reported on the most recent Form 4, priced at the 2013-09-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ENZN | SELL | 2013-09-17 | 2013-09-19 | $1.72 | $96K | -11.7% | -7.1% | -7.1% |
| ENZN | SELL | 2012-08-14 | 2012-08-15 | $6.58 | $38K | -11.7% | -7.1% | -7.1% |
| ENZN | SELL | 2012-08-10 | 2012-08-13 | $6.58 | $13K | -11.7% | -7.1% | -7.1% |
| ENZN | SELL | 2011-06-01 | 2011-06-02 | $10.57 | $92K | -11.7% | -7.1% | -7.1% |
| ENZN | SELL | 2011-02-22 | 2011-02-24 | $10.88 | $109K | -11.7% | -7.1% | -7.1% |
| ENZN | SELL | 2010-08-26 | 2010-08-27 | $10.50 | $105K | -11.7% | -7.1% | -7.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.